Skip to main content
Fig. 3 | EJNMMI Research

Fig. 3

From: The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor

Fig. 3

A single dose of AZD8186 (50 mg/kg) shows no systemic glucose changes and tumour specific modulation 2 h after dosing. a %ID/g biodistribution data in the blood, muscle, lung, liver tumour and bone (mean ± SEM). b Blood glucose concentration pre- and post-dosing (individual animal data). 786-0: vehicle n = 10; AZD8186 n = 10. U87-MG: vehicle n = 8; AZD8186 n = 9. BT474C: vehicle n = 7; AZD87186 n = 8. One-way ANOVA 786-0 p < 0.0001; U87-MG p = 0.0017; BT474C p = 0.002. Student-Newman-Keuls post hoc analysis performed with *p < 0.05 pre- vs post #p < 0.05 vs treatment

Back to article page